Biotechnology Companies Ramp up Funding as Deadly Diseases Come Into the Spotlight
News commentary on marketwatch.com about Algernon Pharmaceuticals. The article addresses how biotechnology is rapidly and continually evolving each year with new innovative therapies and drugs, and how the market valued at USD 399.4 Billion in 2017 is projected to witness a robust CAGR of 9.9% from 2018 to 2024. This news commentary talks about Idiopathic Pulmonary Fibrosis (IPF) studies and how a successful IPF in vivo study for NP-251 would mean that Algernon could begin planning an additional phase II study for its fourth major global disease. A chest radiograph of a patient with IPF. Source: IPFeditor, on Wikipedia Read the full …
FDA Grants Breakthrough Status to Biopharma’s Lead Candidate for Liver Disease
Article from streetwisereports.com discussing how the advancements to Phase 2b are the most valuable asset to CymaBay and many Biotech companies. The research report also addresses how the analyst Yasmeen Rahimi reported that CymaBay Therapeutics had a strong Q1/19 with respect to continued execution of its clinical programs for its most advanced therapeutic, seladelpar, in nonalcoholic steatohepatitis (NASH) and primary biliary cholangitis (PBC). Periportal steatosis of the liver. Source: Nephron Read the full article on the StreetWise Reports website …
About Us
Latest News
